Contract drugmaker Patheon is getting out of agrochemicals and selling off a manufacturing plant, narrowing its focus on pharmaceutical development as it plots an IPO. The company sold a plant in Capua, Italy, to German-headquartered industrial outfit Livia, getting rid of a facility that specializes in small molecules and enzymes. Separately, DPx, Patheon's parent company, sold off its agriculture and fine chemicals businesses to Ardian. Meanwhile, Patheon is preparing for a $100 million U.S. IPO. Livia deal | Ardian acquisition